MCID: HLL004
MIFTS: 53

Hellp Syndrome

Categories: Blood diseases, Cardiovascular diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Hellp Syndrome

MalaCards integrated aliases for Hellp Syndrome:

Name: Hellp Syndrome 12 73 20 58 54 44 15 17 70 32
Hemolysis, Elevated Liver Enzymes, Low Platelets in Pregnancy 58
Hemolysis-Elevated Liver Enzymes-Low Platelets Syndrome 58
Hemolysis, Elevated Liver Enzymes, Lowered Platelets 20

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases
Rare haematological diseases


Summaries for Hellp Syndrome

GARD : 20 HELLP syndrome is a life-threatening condition that can potentially complicate pregnancy. It is named for 3 features of the condition: H emolysis, E levated L iver enzyme levels, and L ow P latelet levels. It typically occurs in the last 3 months of pregnancy (the third trimester) but can also start soon after delivery. A wide range of non-specific symptoms may be present in women with HELLP syndrome. Symptoms may include fatigue; malaise; fluid retention and excess weight gain; headache; nausea and vomiting; pain in the upper right or middle of the abdomen; blurry vision; and rarely, nosebleed or seizures. The cause of HELLP syndrome is not known, but certain risk factors have been associated with the condition. It is most common in women with preeclampsia or eclampsia. If not diagnosed and treated quickly, HELLP syndrome can lead to serious complications for the mother and baby. The main treatment is to deliver the baby as soon as possible, even if premature, if there is distress of the mother or the baby. Treatment may also include medications needed for the mother or baby, and blood transfusion for severe bleeding problems.

MalaCards based summary : Hellp Syndrome, also known as hemolysis, elevated liver enzymes, low platelets in pregnancy, is related to eclampsia and pre-eclampsia. An important gene associated with Hellp Syndrome is HELLPAR (HELLP Associated Long Non-Coding RNA), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Complement and coagulation cascades. The drugs Acetaminophen and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and placenta, and related phenotypes are elevated hepatic transaminase and thrombocytopenia

Disease Ontology : 12 A severe pre-eclampsia characterized by hemolysis, elevated liver enzyme and low platelet count.

Wikipedia : 73 HELLP syndrome is a complication of pregnancy characterized by hemolysis, elevated liver enzymes, and a... more...

Related Diseases for Hellp Syndrome

Diseases related to Hellp Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 416)
# Related Disease Score Top Affiliating Genes
1 eclampsia 32.3 SERPINC1 PGF MTHFR LGALS13 FLT1 F2
2 pre-eclampsia 31.8 VWF SERPINE1 SERPINC1 PGF MTHFR LGALS13
3 severe pre-eclampsia 31.5 SERPINC1 PGF LGALS13 GPT F5 CFH
4 acute kidney failure 31.4 HP GPT F2 CFH ADAMTS13
5 pulmonary edema 31.3 SERPINC1 HP F2
6 fatty liver disease 31.2 SLC17A5 SERPINE1 HADHA GPT
7 disseminated intravascular coagulation 31.2 VWF SERPINE1 SERPINC1 GPT F5 F2
8 placental abruption 31.1 SERPINC1 PGF MTHFR FLT1 F5 F2
9 hepatic infarction 31.0 SERPINC1 GPT F2 APOH
10 intracranial hypotension 31.0 SERPINC1 F2
11 purpura 31.0 VWF SERPINC1 F2 APOH ADAMTS13
12 thrombotic microangiopathy 31.0 VWF HP ADAMTS13
13 acute liver failure 31.0 SLC17A5 GPT F2
14 enterocolitis 30.9 CFH CD46
15 cholecystitis 30.8 HP GPT F2
16 placenta disease 30.7 SERPINC1 PGF MTHFR HADHA FLT1 F5
17 hemoglobinuria 30.7 SERPINC1 HP F2 CFI
18 hepatic coma 30.7 SERPINC1 GPT F2
19 antiphospholipid syndrome 30.6 VWF SERPINE1 SERPINC1 MTHFR F5 F2
20 hepatic encephalopathy 30.6 SLC17A5 GPT F2
21 compartment syndrome 30.6 SLC17A5 SERPINC1 GPT F2
22 thrombophilia 30.6 VWF SERPINE1 SERPINC1 MTHFR F5 F2
23 hemolytic anemia 30.6 VWF HP F2 CFI CFH CD46
24 anuria 30.6 HP F2 ADAMTS13
25 hemolytic-uremic syndrome 30.6 VWF HP F2 CFI CFH CD46
26 hypertensive encephalopathy 30.6 PGF FLT1 F2 ADAMTS13
27 kidney cortex necrosis 30.6 F2 CFI ADAMTS13
28 cholestasis 30.6 SLC17A5 HADHA GPT F2
29 pulmonary embolism 30.5 VWF SERPINE1 SERPINC1 MTHFR F5 F2
30 paroxysmal nocturnal hemoglobinuria 30.4 SERPINC1 HP F2 CFI
31 hemolytic uremic syndrome, atypical 1 30.4 VWF HP CFI CFH CD46 ADAMTS13
32 thrombotic thrombocytopenic purpura 30.4 VWF SERPINC1 HP CFI CFH CD46
33 protein s deficiency 30.4 SERPINC1 MTHFR F5 F2 APOH
34 thrombocytopenia 30.3 VWF SERPINE1 SERPINC1 MTHFR HP GPT
35 bilirubin metabolic disorder 30.3 SLC17A5 SERPINC1 HP GPT F2 ADAMTS13
36 c3 glomerulopathy 30.3 CFI CFH CD46
37 osteonecrosis 30.3 SERPINE1 SERPINC1 MTHFR F2
38 cerebral palsy 30.3 SERPINE1 SERPINC1 MTHFR F5 F2
39 mild pre-eclampsia 30.3 PGF LGALS13 FLT1
40 pregnancy loss, recurrent 1 30.2 F5 APOH
41 cholangitis 30.2 HP GPT F2
42 antithrombin iii deficiency 30.2 SERPINC1 MTHFR F5 F2 APOH
43 retinal vascular disease 30.2 PGF MTHFR FLT1
44 nonarteritic anterior ischemic optic neuropathy 30.2 SERPINC1 MTHFR F5 F2 APOH
45 budd-chiari syndrome 30.2 SERPINC1 MTHFR F5 F2 APOH
46 macular retinal edema 30.2 PGF FLT1 CFH
47 thrombotic thrombocytopenic purpura, hereditary 30.1 HP CFH ADAMTS13
48 catastrophic antiphospholipid syndrome 30.1 SERPINE1 MTHFR F5 CFH APOH ADAMTS13
49 placental insufficiency 30.1 VWF SERPINE1 SERPINC1 PGF FLT1 F2
50 active peptic ulcer disease 30.1 VWF F2

Graphical network of the top 20 diseases related to Hellp Syndrome:



Diseases related to Hellp Syndrome

Symptoms & Phenotypes for Hellp Syndrome

Human phenotypes related to Hellp Syndrome:

58 31 (show all 33)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 elevated hepatic transaminase 58 31 obligate (100%) Obligate (100%) HP:0002910
2 thrombocytopenia 58 31 obligate (100%) Obligate (100%) HP:0001873
3 proteinuria 58 31 frequent (33%) Frequent (79-30%) HP:0000093
4 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
5 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
6 prolonged prothrombin time 58 31 frequent (33%) Frequent (79-30%) HP:0008151
7 preeclampsia 58 31 frequent (33%) Frequent (79-30%) HP:0100602
8 increased body weight 58 31 frequent (33%) Frequent (79-30%) HP:0004324
9 generalized edema 58 31 frequent (33%) Frequent (79-30%) HP:0007430
10 hypofibrinogenemia 58 31 frequent (33%) Frequent (79-30%) HP:0011900
11 maternal hypertension 58 31 frequent (33%) Frequent (79-30%) HP:0008071
12 hypotension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002615
13 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
14 back pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0003418
15 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
16 pleural effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0002202
17 eclampsia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100601
18 poor wound healing 58 31 occasional (7.5%) Occasional (29-5%) HP:0001058
19 disseminated intravascular coagulation 58 31 occasional (7.5%) Occasional (29-5%) HP:0005521
20 hemoglobinuria 58 31 occasional (7.5%) Occasional (29-5%) HP:0003641
21 decreased mean corpuscular hemoglobin concentration 58 31 occasional (7.5%) Occasional (29-5%) HP:0025547
22 pulmonary edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0100598
23 nausea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002018
24 microangiopathic hemolytic anemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001937
25 epigastric pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0410019
26 shoulder pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0030834
27 placental abruption 58 31 occasional (7.5%) Occasional (29-5%) HP:0011419
28 increased lactate dehydrogenase level 31 occasional (7.5%) HP:0025435
29 cerebral hemorrhage 58 31 very rare (1%) Very rare (<4-1%) HP:0001342
30 acute kidney injury 58 31 very rare (1%) Very rare (<4-1%) HP:0001919
31 hemolytic anemia 58 Very frequent (99-80%)
32 internal hemorrhage 58 Very rare (<4-1%)
33 increased lactate dehydrogenase activity 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Hellp Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.9 CD46 CFH F2 F5 FLT1 HADHA
2 homeostasis/metabolism MP:0005376 9.83 ADAMTS13 APOH CFH CFI F2 F5
3 mortality/aging MP:0010768 9.44 ADAMTS13 APOH CFH F2 F5 FLT1

Drugs & Therapeutics for Hellp Syndrome

Drugs for Hellp Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Ibuprofen Approved Phase 4 15687-27-1 3672
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
5
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
6
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
7
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
8 Nutrients Phase 4
9 Micronutrients Phase 4
10 Trace Elements Phase 4
11 Vitamins Phase 4
12 Vitamin D2 Phase 4
13 Ergocalciferols Phase 4
14 Calciferol Phase 4
15 Analgesics, Non-Narcotic Phase 4
16 Analgesics Phase 4
17 Antirheumatic Agents Phase 4
18 Cyclooxygenase Inhibitors Phase 4
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4
20 Antipyretics Phase 4
21 Gastrointestinal Agents Phase 4
22 Antiemetics Phase 4
23 Hormone Antagonists Phase 4
24 Antineoplastic Agents, Hormonal Phase 4
25 Hormones Phase 4
26 glucocorticoids Phase 4
27 BB 1101 Phase 4
28 Anti-Inflammatory Agents Phase 4
29 Pharmaceutical Solutions Phase 4
30
protease inhibitors Phase 4
31 HIV Protease Inhibitors Phase 4
32
Tocopherol Approved, Investigational Phase 3 1406-66-2
33
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
34
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
35 Tocotrienol Investigational Phase 3 6829-55-6
36 Antioxidants Phase 3
37 Tocotrienols Phase 3
38 Tocopherols Phase 3
39 Protective Agents Phase 3
40 Complement System Proteins Phase 2
41
Ethanol Approved 64-17-5 702
42
Fentanyl Approved, Illicit, Investigational, Vet_approved 437-38-7 3345
43
Succinylcholine Approved 306-40-1 5314
44
Thiopental Approved, Vet_approved 76-75-5 3000715
45
Bupivacaine Approved, Investigational 2180-92-9, 38396-39-3 2474
46
Methyldopa Approved 555-30-6 38853
47
Labetalol Approved 36894-69-6 3869
48
Nifedipine Approved 21829-25-4 4485
49
Aspartic acid Approved, Nutraceutical 56-84-8 5960
50 Immunologic Factors

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Unknown status NCT02920593 Phase 4 Vitamin D3
2 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Unknown status NCT02911701 Phase 4 Acetaminophen;Ibuprofen
3 Postpartum Dexamethasone for Women With Class I HELLP Syndrome: a Double-blind, Placebo-controled, Randomized Clinical Trial Terminated NCT00711841 Phase 4 dexamethasone;Placebo;dexamethasone
4 Dexamethasone Efficacy in HELLP I Syndrome, a Multicentric, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01138839 Phase 3 Dexamethasone;sterile water
5 RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil Completed NCT00097110 Phase 3 Vitamin C and E
6 Calcium for Pre-Eclampsia Prevention (CPEP) Completed NCT00000534 Phase 3 calcium
7 Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH Study Not yet recruiting NCT04725812 Phase 2 Eculizumab
8 Eculizumab in HELLP Syndrome Not yet recruiting NCT04103489 Phase 1 Eculizumab
9 Prognostic Value of Human Epididymis Protein 4 (HE4) for Persistent Proteinuria in Women With Severe Preeclampsia / HELLP Syndrome Unknown status NCT03891394
10 Analysis of Serum Pancreatic Stone Protein (PSP) in Healthy Pregnant Women and Its Value in Predicting Inflammatory Complications During Pregnancy Unknown status NCT02247297
11 A Observational Study to Determine the Prevalence of Pregnancy-related Thrombotic Thrombocytopenic Purpura and Atypical Haemolytic Uraemic Syndrome in Women Affected by Specific Obstetric Complications Unknown status NCT03605511
12 Dynamics of Serum Immunologic Markers Levels in During the Delivery and Possible Benefit for Obstetric Emergency Diagnostics Completed NCT03664999
13 General Anesthesia Versus Spinal Anesthesia in Patients of HELLP Syndrome Completed NCT03111446
14 Investigation of the Serum MUC3 Protein Levels in Gestational Hypertensive Disease (Preeclampsia-Eclampsia, Pregnancy Induced Hypertension, and HELLP Syndrome) Compared With Normal Pregnancy Completed NCT04421183
15 Association Between the Quantitative Assessment of Schistocytes in Peripheral Blood Smear and Prognosis of Patient Initially Diagnosed as HELLP Syndrome. Completed NCT03246542
16 Correlation of the Driving Pressure With the Survival of Puerperae Under Mechanical Ventilation by Electrical Impedance Tomography Completed NCT03715647
17 Assessment of Immature Platelet Fraction in Pregnancy-Associated Thrombotic Microangiopathy Completed NCT03232359
18 Comparative Study of Plasma Free DNA and Nucleosome Concentrations: Pathological Versus Normal Pregnancies Completed NCT01736826
19 Early Vascular Adjustments to Prevent Preeclampsia and Related Complications Completed NCT04216706 tailored pharmaceutical treatment
20 Women Specific Cardiac Recovery After Preeclampsia Recruiting NCT02807324
21 EASL: European Registry of Liver Disease in Pregnancy Recruiting NCT03834285
22 The Preeclampsia Registry Recruiting NCT02020174
23 Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy. Recruiting NCT03455387
24 Evaluation of Practicability in Survey and Test Procedures and of Successful Implementation of Complex Interventions - Feasibility Analysis Based on a Pilot Study: Influence of Conditional Workout Postpartum on Arterial Stiffness Among Women With Status After Preeclampsia, Superimposed Preeclampsia or HELLP-syndrome Active, not recruiting NCT02754778
25 Pregnancy-Related Hypertension: Adherence to a New Type of Monitoring Not yet recruiting NCT04823949

Search NIH Clinical Center for Hellp Syndrome

Cochrane evidence based reviews: hellp syndrome

Genetic Tests for Hellp Syndrome

Anatomical Context for Hellp Syndrome

MalaCards organs/tissues related to Hellp Syndrome:

40
Liver, Kidney, Placenta, Endothelial, Brain, Neutrophil, Breast

Publications for Hellp Syndrome

Articles related to Hellp Syndrome:

(show top 50) (show all 2339)
# Title Authors PMID Year
1
Conservative versus active management in HELLP syndrome: results from a cohort study. 20 61
29228827 2019
2
The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with HELLP syndrome. 54 61
18058192 2009
3
Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. 61 54
19190814 2009
4
Acute fatty liver of pregnancy and neonatal long-chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) deficiency. 54 61
18408953 2009
5
HELLP syndrome is associated with an increased inflammatory response, which may be inhibited by administration of prednisolone. 61 54
18696354 2008
6
Maternal factor V Leiden mutation is associated with HELLP syndrome in Caucasian women. 54 61
18568463 2008
7
The presence of active von Willebrand factor under various pathological conditions. 61 54
17414220 2007
8
Reduced pseudocholinesterase activity in patients with HELLP syndrome. 61 54
17636231 2007
9
Characteristic laboratory changes in pregnancies complicated by HELLP syndrome. 61 54
18066958 2007
10
Neither maternal nor fetal mutation (E474Q) in the alpha-subunit of the trifunctional protein is frequent in pregnancies complicated by HELLP syndrome. 54 61
17313315 2007
11
Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. 61 54
16968329 2006
12
Maternal heterozygosity for a mitochondrial trifunctional protein mutation as a cause for liver disease in pregnancy. 61 54
15533621 2005
13
Lack of correlation between fatty acid oxidation disorders and haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome? 54 61
15858960 2005
14
Obstetric implications of antepartum corticosteroid therapy for HELLP syndrome. 54 61
15516393 2004
15
Pseudocholinesterase deficiency associated with HELLP syndrome. 61 54
15311366 2004
16
[Pregnancy complicated by HELLP syndrome]. 54 61
15884197 2004
17
Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. 54 61
12969811 2003
18
Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. 54 61
14526324 2003
19
Anticardiolipin and anti-beta2-glycoprotein-I antibodies in preeclampsia. 54 61
12907102 2003
20
[Pregnancy and inborn errors of metabolism]. 61 54
12931456 2003
21
[Antiphospholipid antibodies in HELLP syndrome: clinical and biological study in 68 women]. 61 54
12657437 2003
22
Haptoglobin and its association with the HELLP syndrome. 54 61
12624142 2003
23
The evaluation of maternal parameters at diagnosis may predict HELLP syndrome severity. 61 54
12820835 2003
24
Correlation of platelet count changes with liver cell destruction in HELLP syndrome. 54 61
12648443 2003
25
Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome. 61 54
12519104 2002
26
Gestational thrombocytopenia and pregnancy-induced antithrombin deficiency: progenitors to the development of the HELLP syndrome and acute fatty liver of pregnancy. 61 54
12536342 2002
27
ProC Global assay in the evaluation of women with history of severe preeclampsia or HELLP syndrome. 54 61
12518722 2002
28
[The impact of pregnancy-prolonging management on maternal and neonatal morbidity in HELLP syndrome]. 61 54
11709744 2001
29
Serum soluble Fas in the syndrome of hemolysis, elevated liver enzymes, and low platelets. 61 54
11506848 2001
30
[Hemolytic uremic syndrome in twin pregnancy at 32 weeks gestation with HELLP syndrome. Case report]. 61 54
11431643 2001
31
Hyperhomocysteinaemia: a risk factor for preeclampsia? 54 61
11301178 2001
32
A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia. 61 54
11283205 2001
33
HELLP syndrome and factor V Leiden. 54 61
11267721 2001
34
Doppler velocimetry and non stress test in severe fetal growth restriction. 61 54
11332586 2001
35
Efficacy of haptoglobin administration in the early postoperative course of patients with a diagnosis of HELLP syndrome. 54 61
15512676 2000
36
Liver disease in pregnancy and fetal fatty acid oxidation defects. 61 54
11001809 2000
37
Heterozygosity for the common LCHAD mutation (1528g>C) is not a major cause of HELLP syndrome and the prevalence of the mutation in the Dutch population is low. 61 54
10926288 2000
38
Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase. 61 54
10877984 2000
39
Methylenetetrahydrofolate reductase polymorphisms in preeclampsia and the HELLP syndrome. 54 61
11118403 2000
40
Inherited long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. 61 54
10331463 1999
41
Can the laboratory assay of protein C activity assist in monitoring the hemostatic function in pre-eclampsia? 61 54
10357006 1999
42
Association of a decrease in antithrombin III activity with a perinatal elevation in aspartate aminotransferase in women with twin pregnancies: relevance to the HELLP syndrome. 61 54
10207801 1999
43
Plasma glutathione S-transferase Pi 1-1 measurements in the study of hemolysis in hypertensive disorders of pregnancy. 61 54
10476616 1999
44
Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. 61 54
9721789 1998
45
Triplet pregnancy complicated by a gradual decline in antithrombin-III activity and HELLP syndrome: a case report. 54 61
9798357 1998
46
Extensive hepatic infarction caused by thrombosis of right portal vein branches and arterial vasospasm in HELLP syndrome associated with homozygous factor V Leiden. 54 61
9517665 1998
47
Inherited metabolic diseases affecting the carrier. 61 54
9061562 1997
48
Eclampsia after polychemotherapy for nodal-positive breast cancer during pregnancy. 54 61
8841812 1996
49
Reproductive effects of maternal metabolic disorders: implications for pediatrics and obstetrics. 54 61
8827903 1996
50
[Lactate dehydrogenase isoenzymes in patients with HELLP syndrome]. 61 54
8963883 1996

Variations for Hellp Syndrome

Expression for Hellp Syndrome

Search GEO for disease gene expression data for Hellp Syndrome.

Pathways for Hellp Syndrome

Pathways related to Hellp Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.56 VWF SERPINE1 SERPINC1 F5 F2
2 11.39 VWF SERPINE1 SERPINC1 F5 F2 CFI
3
Show member pathways
10.36 PGF FLT1

GO Terms for Hellp Syndrome

Cellular components related to Hellp Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.9 VWF SERPINE1 SERPINC1 HP GSTP1 GPT
2 extracellular region GO:0005576 9.77 VWF SERPINE1 SERPINC1 PGF HP GSTP1
3 endoplasmic reticulum lumen GO:0005788 9.73 SERPINC1 F5 F2 ADAMTS13
4 collagen-containing extracellular matrix GO:0062023 9.72 VWF SERPINE1 SERPINC1 F2 APOH
5 blood microparticle GO:0072562 9.56 SERPINC1 HP F2 CFH
6 platelet alpha granule lumen GO:0031093 9.54 VWF SERPINE1 F5
7 extracellular space GO:0005615 9.47 VWF SERPINE1 SERPINC1 PGF HP GSTP1
8 platelet alpha granule GO:0031091 9.4 VWF F5

Biological processes related to Hellp Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.77 VWF SERPINC1 F5 F2 ADAMTS13
2 platelet degranulation GO:0002576 9.73 VWF SERPINE1 F5 APOH
3 regulation of complement activation GO:0030449 9.71 F2 CFI CFH CD46
4 platelet activation GO:0030168 9.65 VWF F2 ADAMTS13
5 blood coagulation, intrinsic pathway GO:0007597 9.5 VWF F2 APOH
6 negative regulation of blood coagulation GO:0030195 9.46 SERPINE1 APOH
7 positive regulation of blood coagulation GO:0030194 9.43 SERPINE1 F2 APOH
8 regulation of blood coagulation GO:0030193 9.33 SERPINC1 F2 APOH
9 negative regulation of fibrinolysis GO:0051918 9.13 SERPINE1 F2 APOH
10 hemostasis GO:0007599 9.02 VWF SERPINC1 F5 F2 ADAMTS13

Molecular functions related to Hellp Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.13 VWF SERPINE1 SERPINC1
2 heparin binding GO:0008201 9.02 SERPINC1 PGF F2 CFH APOH

Sources for Hellp Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....